Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash & Current Investments (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Cash & Current Investments data on record, last reported at $30.5 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 22.12% year-over-year to $30.5 million; the TTM value through Sep 2025 reached $30.5 million, down 22.12%, while the annual FY2024 figure was $41.9 million, 7.27% down from the prior year.
  • Cash & Current Investments reached $30.5 million in Q3 2025 per SGMO's latest filing, down from $38.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $587.1 million in Q1 2021 and bottomed at $25.2 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $190.5 million, with a median of $100.4 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: soared 63.93% in 2021, then crashed 80.58% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $376.5 million in 2021, then crashed by 73.33% to $100.4 million in 2022, then plummeted by 55.0% to $45.2 million in 2023, then decreased by 7.27% to $41.9 million in 2024, then decreased by 27.17% to $30.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $30.5 million in Q3 2025, $38.3 million in Q2 2025, and $25.2 million in Q1 2025.